Valder R Arruda
Overview
Explore the profile of Valder R Arruda including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
85
Citations
5459
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Azhwar R, Richter C, Griffin M, Emly S, Yaman M, Arruda V, et al.
Blood Adv
. 2025 Mar;
PMID: 40085950
Deficiencies in coagulation factor VIII (FVIII, F8) result in the bleeding disorder hemophilia A. An emerging novel therapeutic strategy for bleeding disorders is to enhance hemostasis by limiting natural anticoagulants,...
2.
Richter C, Raghunath A, Griffin M, Yaman M, Arruda V, Samelson-Jones B, et al.
bioRxiv
. 2025 Feb;
PMID: 39896458
Deficiencies in coagulation factor VIII (FVIII, ) result in the bleeding disorder hemophilia A. An emerging novel therapeutic strategy for bleeding disorders is to enhance hemostasis by limiting natural anticoagulants,...
3.
Doshi B, Samelson-Jones B, Nichols T, Merricks E, Siner J, French R, et al.
Mol Ther Methods Clin Dev
. 2024 Feb;
32(1):101205.
PMID: 38374963
The hemophilias are the most common severe inherited bleeding disorders and are caused by deficiency of clotting factor (F) VIII (hemophilia A) or FIX (hemophilia B). The resultant bleeding predisposition...
4.
Van Gorder L, Doshi B, Willis E, Nichols T, Cook E, Everett J, et al.
Mol Ther Methods Clin Dev
. 2023 Dec;
31:101159.
PMID: 38094200
Adeno-associated viral (AAV) vectors have traditionally been viewed as predominantly nonintegrating, with limited concerns for oncogenesis. However, accumulating preclinical data have shown that AAV vectors integrate more often than previously...
5.
Ivanciu L, Arruda V, Camire R
Blood
. 2023 Feb;
141(16):2022-2032.
PMID: 36724452
Factor IXa (FIXa) plays a pivotal role in coagulation by contributing to FX activation via the intrinsic pathway. Although antithrombin (AT) and other plasma inhibitors are thought to regulate FIXa...
6.
Pipe S, Arruda V, Lange C, Kitchen S, Eichler H, Wadsworth S
Curr Gene Ther
. 2022 Sep;
23(2):81-95.
PMID: 36111754
Hemophilia A, a single gene disorder leading to deficient Factor VIII (FVIII), is a suitable candidate for gene therapy. The aspiration is for single administration of a genetic therapy that...
7.
Arruda V, Lillicrap D, Herzog R
Blood
. 2022 Jul;
140(10):1075-1085.
PMID: 35793465
Disorders of coagulation, resulting in serious risks for bleeding, may be caused by autoantibody formation or by mutations in genes encoding coagulation factors. In the latter case, antidrug antibodies (ADAs)...
8.
Arruda V
Blood Adv
. 2021 Oct;
5(20):4313.
PMID: 34698767
The prospect of a clinical strategy using an adeno-associated virus (AAV) vector for expression of therapeutic levels of factor VIII (FVIII) has been highly desirable. This was initially anticipated by...
9.
Samelson-Jones B, Finn J, Raffini L, Merricks E, Camire R, Nichols T, et al.
Blood Adv
. 2021 Mar;
5(5):1324-1332.
PMID: 33656538
The high-specific-activity factor IX (FIX) variant Padua (R338L) is the most promising transgene for hemophilia B (HB) gene therapy. Although R338 is strongly conserved in mammalian evolution, amino acid substitutions...
10.
Doshi B, Rana J, Castaman G, Shaheen M, Kaczmarek R, Butterfield J, et al.
J Clin Invest
. 2021 Mar;
131(8).
PMID: 33651716
Inhibitors of factor VIII (FVIII) remain the most challenging complication of FVIII protein replacement therapy in hemophilia A (HA). Understanding the mechanisms that guide FVIII-specific B cell development could help...